Yesterday, a Director at CareDx (CDNA), Michael Goldberg, sold shares of CDNA for $1.87M.
Following Michael Goldberg’s last CDNA Sell transaction on July 23, 2014, the stock climbed by 28.2%.
See today’s analyst top recommended stocks >>
Based on CareDx’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $23.51 million and GAAP net loss of $3.76 million. In comparison, last year the company earned revenue of $12.5 million and had a GAAP net loss of $31.67 million. Currently, CareDx has an average volume of 1.15M. The Company has a Price to Book ratio of 16.4586.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $36.25, reflecting a -5.0% downside.
The insider sentiment on CareDx has been positive according to 73 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Michael Goldberg’s trades have generated a 21.1% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CareDx, Inc. operates as a transplant diagnostics company,which discovers, develops, and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure, and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.